Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01573052
Recruitment Status : Completed
First Posted : April 6, 2012
Last Update Posted : June 21, 2012
Information provided by (Responsible Party):
Christopher J. Stock, PharmD, VA Salt Lake City Health Care System

Brief Summary:
A randomized, double-blind controlled trial comparing treatment outcomes between chloriazepide, or gabapentin to treat alcohol withdrawal syndrome in alcohol dependent veteran subjects. The objective of this trial is to compare the safety and effectiveness of these two medications. Intervention is a fixed dose taper of chlordiazepoxide, or gabapentin over 6 days. Subjects will be evaluated for 7-10 days to monitor alcohol abstinence, withdrawal severity scores, adverse events including ataxia, sedation, cognitive function and alcohol craving.

Condition or disease Intervention/treatment Phase
Alcohol Withdrawal Drug: Chlordiazepoxide Drug: Gabapentin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Chlordiazepoxide and Gabapentin for Outpatient Alcohol Detoxification Treatment
Study Start Date : March 2004
Actual Primary Completion Date : August 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Chlordiazepoxide Drug: Chlordiazepoxide
25mg qid x 3 days then tapered over 3 days

Experimental: Gabapentin Drug: Gabapentin
300mg qid x 3 days then tapered over 3 days

Primary Outcome Measures :
  1. Epworth Sleepiness Scale [ Time Frame: 1 week ]
  2. PENN Alcohol Craving Scale [ Time Frame: 1 week ]

Secondary Outcome Measures :
  1. Ataxia [ Time Frame: 1 week ]
    Brief neurological exam for coordination including assessment of stance, tandem gait, romberg test, pronator drift, toe and heel walk, rapid-alternating-movements, and point-to-point movements

  2. Withdrawal assessment scale [ Time Frame: 1 week ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Alcohol dependent at risk for withdrawal symptoms

Exclusion Criteria:

  • Benzodiazepine dependent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01573052

Layout table for location information
United States, Utah
George E Wahlen VA Medical Center
Salt Lake City, Utah, United States, 84148
Sponsors and Collaborators
VA Salt Lake City Health Care System
Layout table for investigator information
Principal Investigator: Christopher J Stock, PharmD Salt Lake VA Health Care System

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Christopher J. Stock, PharmD, Investigational pharmacist, VA Salt Lake City Health Care System Identifier: NCT01573052    
Other Study ID Numbers: UU40574
First Posted: April 6, 2012    Key Record Dates
Last Update Posted: June 21, 2012
Last Verified: June 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antimanic Agents
Adjuvants, Anesthesia
Hypnotics and Sedatives
GABA Modulators
GABA Agents